Overview |
bsm-54425R |
Methionine Aminopeptidase 2 (2G3) Monoclonal Antibody |
WB, FCM, IHC-P, IF(IHC-P), IF(ICC) |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Recombinant protein within C-terminal human Methionine Aminopeptidase 2. |
Monoclonal |
2G3 |
IgG |
1ug/ul |
Purified by Protein A. |
Aqueous buffered solution containing 1xTBS (pH7.4), 1%BSA, 40%Glycerol and 0.05% Sodium Azide. |
Store at -20°C for 12 months. |
Target |
10988 |
P50579 |
Cytoplasm |
Methionine aminopeptidase 2; Initiation factor 2-associated 67 kDa glycoprotein; Peptidase M; MetAP 2; p67; p67eIF2; METAP2; MNPEP; P67EIF2 |
Methionine aminopeptidases (MetAP), also designated peptidase M proteins, are members of the M24 family of proteins. Both MetAP-1 and MetAP-2 release N-terminal amino acids, usually methionine, from nascent peptides and arylamines. Eukaryotes contain both MetAP-1 and MetAP-2, whereas prokaryotes possess only the MetAP-1 enzyme. MetAP-1 and MetAP-2 control cell proliferation in mammalian cells. MetAP-2 is highly conserved between human and Saccharomyces cerevisiae. Neurofibromin (NF1) regulates MetAp-2 and increased expression of MetAP-2 correlates with several forms of cancer. Inhibitors of MetAP-2 are potential targets in cancer therapeutics, particularly in NF1-associated tumor proliferation. Chemotherapeutic drugs such as ovalicin and fumagillin bind to the active site of and inhibit MetAp-2. |
Application Dilution |
WB |
1:300-5000 |
FCM |
1:20-100 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |
IF(ICC) |
1:50-200 |